SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Eric J. Topol, M.D., to its board of directors and chair of the Company’s science and technology committee. Dr. Topol brings to MyoKardia more than 30 years of expertise in cardiovascular medicine and genetics. As a researcher, he has published approximately 1,100 peer-reviewed articles, with more than 160,000 citations, has been elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine.
Help employers find you! Check out all the jobs and post your resume.
